Management of High-Risk Myeloma

In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies. Here are the key studies that we touched upon:
1. Phase II OPTIMUM/MUKnine trial in ultra-high-risk myeloma and PCL:
pubmed.ncbi.nlm.nih.gov/37315...
2. Meta-analysis of more than 2500 patients with chromosome 1q21 abnormalities:
pubmed.ncbi.nlm.nih.gov/34092...
3. Predicting ultra-high risk myeloma by molecular profiling, including SKY92 GEP signature:
pubmed.ncbi.nlm.nih.gov/32157...
4. French data on adverse prognostic impact of del1p32:
pubmed.ncbi.nlm.nih.gov/36375...
5. S1211 study: The first high-risk enrichment RCT in myeloma-VRD vs Elo-VRD: pubmed.ncbi.nlm.nih.gov/33357...
6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial: ashpublications.org/blood/art...
7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma, including double-hits:
pubmed.ncbi.nlm.nih.gov/35731...
8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:
pubmed.ncbi.nlm.nih.gov/34732...